SG11202109055UA - Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy - Google Patents
Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapyInfo
- Publication number
- SG11202109055UA SG11202109055UA SG11202109055UA SG11202109055UA SG11202109055UA SG 11202109055U A SG11202109055U A SG 11202109055UA SG 11202109055U A SG11202109055U A SG 11202109055UA SG 11202109055U A SG11202109055U A SG 11202109055UA SG 11202109055U A SG11202109055U A SG 11202109055UA
- Authority
- SG
- Singapore
- Prior art keywords
- gammadelta
- homing
- therapy
- retention
- cells
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 230000014759 maintenance of location Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809671P | 2019-02-24 | 2019-02-24 | |
| PCT/IL2020/050206 WO2020170260A1 (en) | 2019-02-24 | 2020-02-24 | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109055UA true SG11202109055UA (en) | 2021-09-29 |
Family
ID=72143612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109055UA SG11202109055UA (en) | 2019-02-24 | 2020-02-24 | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220143086A1 (https=) |
| EP (1) | EP3927353A4 (https=) |
| JP (2) | JP7546582B2 (https=) |
| KR (1) | KR20210133996A (https=) |
| CN (1) | CN113710257A (https=) |
| AU (1) | AU2020225597A1 (https=) |
| BR (1) | BR112021016698A2 (https=) |
| CA (1) | CA3130442A1 (https=) |
| IL (1) | IL285806B2 (https=) |
| SG (1) | SG11202109055UA (https=) |
| WO (1) | WO2020170260A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3130442A1 (en) * | 2019-02-24 | 2020-08-27 | Gamida Cell Ltd. | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
| WO2023069322A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
| KR20250172550A (ko) * | 2023-01-17 | 2025-12-09 | 안선 바이오파르마, 아이엔씨. | 감마 델타 t 세포의 생성 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| EP3184109B1 (en) * | 2009-12-29 | 2020-11-18 | Gamida-Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
| CN102154205A (zh) * | 2011-01-31 | 2011-08-17 | 郑骏年 | 高纯度、高细胞毒活性的γδT细胞的制备方法 |
| EP3060059A4 (en) | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| IL297773B2 (en) * | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| SG11201803419PA (en) * | 2015-10-30 | 2018-05-30 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
| AU2017340644B2 (en) * | 2016-10-05 | 2024-05-09 | FUJIFILM Cellular Dynamics, Inc. | Methods for directed differentiation of pluripotent stem cells to HLA homozygous immune cells |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
| US12440578B2 (en) * | 2017-02-22 | 2025-10-14 | Io Biosciences, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
| CN107164322A (zh) * | 2017-07-05 | 2017-09-15 | 泰山医学院附属医院 | 一种用于人γδT细胞扩增的培养基及其制备方法 |
| CN108949685B (zh) * | 2018-08-02 | 2022-03-29 | 吉林大学第一医院 | 一种体外诱导扩增高杀伤活性γδT细胞的方法 |
| CA3130442A1 (en) * | 2019-02-24 | 2020-08-27 | Gamida Cell Ltd. | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
-
2020
- 2020-02-24 CA CA3130442A patent/CA3130442A1/en active Pending
- 2020-02-24 IL IL285806A patent/IL285806B2/en unknown
- 2020-02-24 KR KR1020217030744A patent/KR20210133996A/ko not_active Ceased
- 2020-02-24 BR BR112021016698-0A patent/BR112021016698A2/pt unknown
- 2020-02-24 SG SG11202109055UA patent/SG11202109055UA/en unknown
- 2020-02-24 WO PCT/IL2020/050206 patent/WO2020170260A1/en not_active Ceased
- 2020-02-24 US US17/432,758 patent/US20220143086A1/en not_active Abandoned
- 2020-02-24 AU AU2020225597A patent/AU2020225597A1/en active Pending
- 2020-02-24 CN CN202080030540.8A patent/CN113710257A/zh active Pending
- 2020-02-24 EP EP20759171.0A patent/EP3927353A4/en not_active Withdrawn
- 2020-02-24 JP JP2021549565A patent/JP7546582B2/ja active Active
-
2024
- 2024-04-03 JP JP2024060371A patent/JP2024088717A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521027A (ja) | 2022-04-04 |
| IL285806A (en) | 2021-10-31 |
| US20220143086A1 (en) | 2022-05-12 |
| CN113710257A (zh) | 2021-11-26 |
| EP3927353A4 (en) | 2022-11-23 |
| EP3927353A1 (en) | 2021-12-29 |
| IL285806B2 (en) | 2025-05-01 |
| AU2020225597A1 (en) | 2021-10-07 |
| BR112021016698A2 (pt) | 2021-10-13 |
| IL285806B1 (en) | 2025-01-01 |
| JP7546582B2 (ja) | 2024-09-06 |
| JP2024088717A (ja) | 2024-07-02 |
| WO2020170260A1 (en) | 2020-08-27 |
| CA3130442A1 (en) | 2020-08-27 |
| KR20210133996A (ko) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550846A1 (en) | Compositions and methods for expressing factor ix | |
| IL291579A (en) | cbl inhibitors and compositions for use in cell stress therapy | |
| SG11202104524YA (en) | Compositions and methods for t cell engineering | |
| ZA202310779B (en) | Compositions and methods for enhanced gene expression | |
| GB2561496A (en) | Devices and methods for simulating a function of a liver tissue | |
| SG11202109055UA (en) | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy | |
| SG10202107602XA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| IL282447A (en) | Methods and preparations for healing eye cell | |
| GB2562396A (en) | Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof | |
| WO2012048010A3 (en) | Compositions of adult organ stem cells and uses thereof | |
| EP3914271A4 (en) | COMPOSITIONS AND METHODS OF GENERATION OF HEMATOPOETIC STEM CELLS (HSCS) | |
| GB2608279B (en) | Therapeutic cell compositions and methods for manufacture and uses thereof | |
| SG11202107904PA (en) | Compositions and methods for stimulating natural killer cells | |
| IL288260A (en) | Preparations and methods for plant cell culture | |
| SG11202109510YA (en) | Modulators of cell surface protein interactions and methods and compositions related to same | |
| EP3645020A4 (en) | COMPOSITIONS AND PROCEDURES FOR ADOPTIVE CELL THERAPY | |
| IL319935A (en) | Compositions and methods for improving T cell therapy | |
| KR102325857B9 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 | |
| IL287981A (en) | Preparations and methods for the treatment of t-cell exhaustion | |
| EP3750577A4 (en) | INJECTOR AND METHOD OF INJECTING SOLUTION CONTAINING LIVE CELLS INTO TARGET CELL NUCLEUS INJECTION BY MEANS OF THE INJECTOR | |
| AU2017254665A1 (en) | Compositions and methods for enhanced gene expression of pklr | |
| GB201800184D0 (en) | Compositions and methods for delivery of nucleic acid plant cells | |
| PL3652292T3 (pl) | Naczynie do hodowli komórkowej 3d i sposoby hodowli komórkowej 3d | |
| SG11202102538RA (en) | Compositions and methods for transfecting cells | |
| IL287387A (en) | Cell culture media for eukaryotic cells |